Study highlights risk groups for a severe side effect of diabetes treatment
A study of over 280,000 patients reveals that type 2 diabetes patients with low body weight, high blood glucose, or a history of ketoacidosis face increased risks when using SGLT2 inhibitors. Researchers emphasize that these risks persist throughout the entire treatment duration.
Why it matters
Understanding these risk factors is critical for clinicians to prevent life-threatening ketoacidosis in patients managing diabetes with SGLT2 inhibitors.
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain Patients with type 2 diabetes who have high blood glucose levels, low body weight or a history of ketoacidosis are at increased risk of developing this serious condition when treated with so-called SGLT2 inhibitors. A study led by researchers at Karolinska Institutet also shows that the risk persists throughout the entire course of treatment.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in